ABVC BioPharma, Inc. (ABVC)

1,1100 +0,0500 (+4,72%) Alla chiusura: 04:00PM EDT

ABVC BioPharma, Inc.

44370 Old Warm Springs Boulevard
Fremont, CA 94538
United States
(510)-668-0881
https://www.abvcpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 16

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Eugene Jiang	Chairman & Chief Business Officer	200k	N/D	1986
Dr. Uttam Yashwant Patil Ph.D.	Chief Executive Officer	N/D	N/D	1986
Mr. Leeds Chow	CFO & Principal Accounting Officer	180k	N/D	1989
Dr. Tsung-Shann Jiang EMBA, Ph.D.	Chief Scientific Officer, Chief Strategy Officer & Director	200k	N/D	1954

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Governance aziendale

L'ISS Governance QualityScore di ABVC BioPharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.